About Us: Leadership
Brian P. McVeigh, MBA, CPA, CMA, CLP
Chief Executive Officer
Brian McVeigh is the Chairman, Chief Executive Officer, and Co-Founder of Code Bio. He also serves as the Executive Chairman of Redpin Therapeutics, Chairman of the Board of Genisphere, LLC, Board Observer of Araris Biotech AG, and is a Venture Partner with 4BIO Capital.
Brian has held leadership roles in both private and public biotechs, including a 25-year career with GlaxoSmithKline (GSK) Pharmaceuticals where he most recently served as the Vice President of Worldwide Business Development Transactions and Investment Management. In that capacity, he oversaw the assessment, negotiation, and execution of more than 100 business development transactions and managed GSK R&D’s $500+ million portfolio of equity investments in biotech collaboration partners and venture capital funds.
Brian holds Bachelor of Science degrees in Accounting and Finance from LaSalle University, an MBA with a Concentration in Finance from Villanova University, a Post MBA Certificate in Pharmaceutical Marketing from Saint Joseph's University, and a Certificate of Professional Development from the Wharton Business School at the University of Pennsylvania. He is a Certified Public Accountant, Certified Management Accountant, and Certified Licensing Professional.
Robert C. Getts, Ph.D.
Chief Technology Officer
Dr. Bob Getts serves as Chief Technology Officer and is a Co-Founder of Code Bio. Bob leads all of the company’s discovery, platform development and novel application activities. He also serves as a Scientific Advisor for AllerGenis LLC; as a member of the Rowan University Biomedical Engineering Industrial and Medical Advisory Board; as an Associate Clinical Preceptor of Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy; and as a graduate program advisor at Thomas Jefferson University and The University of Maryland.
Bob possesses more than 25 years of experience using nanotechnologies as tools to develop life science reagents, kits, and diagnostic assays. Most recently he served as the Chief Scientific Officer and acting CEO at Genisphere, LLC. where he led the development of 3DNA as a novel non-viral targeted delivery platform for the delivery of multiple types of therapeutic cargo including small drugs, siRNA, biologics, and whole genes.
Bob has a Ph.D. in Biochemistry from Lehigh University, has over 40 peer-review publications, abstracts, and presentations, and is listed as an inventor on more than 20 issued patents and over 35 U.S. and international patent applications.
Lauren M. Kaskiel, MBA
Chief Business Officer
Lauren Kaskiel has 20 years of experience in the biotech and pharmaceutical industry and joins Code Bio from Spark Therapeutics where she most recently served as Head of Program and Alliance Management. During her time at Spark, Lauren held roles in Alliance Management, New Product Planning and Program Management and established and managed key strategic relationships on gene therapy programs with Pfizer and Novartis. Lauren most recently served as a liaison with the Roche Group to support engagement and interactions during the first year following the acquisition of Spark by the Roche Group in December of 2019, and contributed to defining the operating model and governance for Spark and served as Chief of Staff to the Executive Team. Previously, Lauren was at GlaxoSmithKline (GSK) in research, operations, strategy, and alliance management roles. As part of GSK’s Worldwide Business Development team, Lauren managed over 20 alliances with biotech, diagnostic and venture partners.
She holds a Bachelor of Science degree in Biotechnology with a Minor in Microbiology from Pennsylvania State University and an MBA with a Concentration in Marketing from Drexel University. She has her Certificate of Achievement in Alliance Management (CA-AM) through the Association of Strategic Alliance Professionals (ASAP), is President of the ASAP Tri-State Chapter, and is a frequent guest lecturer at both Penn State and Drexel Universities.
Lori A. Getts, Ph.D.
Vice President, Preclinical and Process Development
Dr. Lori Getts is the Vice President of Preclinical and Process Development and a Co-Founder of Code Bio. Lori leads the process scale up, CMC, and preclinical development functions for all of our pipeline programs. She has 20+ years’ experience in the biotech industry, developing therapeutic drug delivery platforms for targeted therapeutics, as well as developing and commercializing reagents and research kits used in a variety of biological assays throughout the life sciences and diagnostic sectors.
Lori was most recently the Vice President of Preclinical and Process Development at Genisphere, LLC where she played a pivotal role in the development of the 3DNA platform. She also directed the manufacture and QC of Genisphere’s entire reagents and research kit product line (over 135 products) including the OEM manufacture of the company’s flagship product, FlashTag®.
Lori is a co-author of many posters and papers as well as a co-inventor on several of the company’s patents and patent applications. She received her Ph.D. in Chemistry (Biochemistry focus) from Lehigh University and completed her Ph.D. thesis at Fox Chase Cancer Center where she used ovarian cancer model systems to study ovarian cancer etiology.